Table 1. Demographic and clinical characteristics of adult patients at ART initiation – Mozambique, 2004–2007.
| Original Data | Following MultipleImputation (N = 2,596) | |||||
| Un-weighted Frequency of Observations | Un-weighted Total | Weighted Median with IQR*, or, Percentage with 95% CI | Weighted Median with IQR*,or, Percentage with 95% CI | |||
| Median Age † , No., N, median (IQR) | ||||||
| Both Sexes | 2,596 | 2,596 | 34 | (28–42) | 34 | (28–42) |
| Female | 1,576 | 1, 576 | 32 | (27–39) | 32 | (27–39) |
| Male | 1,020 | 1,020 | 38 | (31–45) | 38 | (31–45) |
| Female † , No., N, %, (95% CI) | 1,576 | 2,596 | 62% | (59–65%) | 62% | (59–65%) |
| Employment status, No., N, %, (95% CI) | ||||||
| Employed | 992 | 2,268 | 46% | (40–51%) | 45% | (40–51%) |
| Student | 107 | 2,268 | 4% | (3–5%) | 4% | (3–5%) |
| Unemployed | 1,169 | 2,268 | 50% | (45–56%) | 51% | (46–56%) |
| observations missing data** | 328 | 2,596 | 13% | |||
| Active TB, No., N, %, (95% CI) | 267 | 2,564 | 11% | (9–13%) | 11% | (9–13%) |
| observations missing data** | 32 | 2,596 | 1% | |||
| WHO Stage, No., N, %, (95% CI) | ||||||
| I/II | 619 | 1,617 | 37% | (32–42%) | 40% | (34–45%) |
| III | 739 | 1,617 | 47% | (43–52%) | 45% | (40–50%) |
| IV | 259 | 1,617 | 16% | (13–18%) | 15% | (13–18%) |
| observations missing data** | 979 | 2,596 | 38% | |||
| Weight Category, No., N, % (95% CI) | ||||||
| <45 kg | 367 | 2,061 | 17% | (14–20%) | 18% | (15–21%) |
| 45–60 kg | 1,224 | 2,061 | 59% | (56–61%) | 57% | (54–59%) |
| > 60 kg | 470 | 2,061 | 24% | (21–27%) | 25% | (22–28%) |
| observations missing data** | 535 | 2,596 | 21% | |||
| BMI<18.5, No., N, %, (95% CI) | 354 | 1,200 | 28% | (23–33%) | 28% | (23–33%) |
| observations missing data** | 1,396 | 2,596 | 54% | |||
| CD4+ T-cell count, No., N, median (IQR) | ||||||
| Both Sexes | 2,254 | 2,596 | 155 | (76–231) | 153 | (74–231) |
| Female | 1,373 | 1,576 | 161 | (88–244) | 159 | (87–243) |
| Male | 881 | 1,020 | 141 | (59–213) | 139 | (59–213) |
| observations missing data** | 342 | 2,596 | 13% | |||
| Hemoglobin, No., N, median (IQR) | ||||||
| Both Sexes | 1,899 | 2,596 | 10.1 | (8.8–11.6) | 10.3 | (8.8–11.7) |
| Female | 1,182 | 1,576 | 9.8 | (8.6–11.0) | 9.9 | (8.5–11.1) |
| Male | 717 | 1,020 | 11.1 | (9.0–12.5) | 11.0 | (9.2–12.5) |
| First Line ART Regimens † , No., N, %, (95% CI) | ||||||
| D4T + 3TC + NVP/EFV | 2,315 | 2,596 | 88% | (82–94%) | 88% | (82–94%) |
| AZT + 3TC + NVP/EFV | 240 | 2,596 | 11% | (5–16%) | 11% | (5–16%) |
| D4T/AZT + 3TC + ABC | 17 | 2,596 | <1% | (0–1%) | <1% | (0–1%) |
| Other | 24 | 2,596 | <1% | (0–1%) | <1% | (0–1%) |
Abbreviations: CI, confidence interval; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization; Kgs, kilograms; BMI, body mass index; ART, antiretroviral therapy; D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; AZT, zidovudine; ABC, abacavir; CTX, co-trimoxazole.
*Median and IQR calculated across 20 imputed datasets.
†
Variables with complete data.
**Unweighted sample estimate.